TapImmune Inc. (TPIV) Is Pleased To Announce The Filing Of New Intellectual Property Surrounding Its Novel And Proprietary Platform Expression System Polystart™
3/20/2014 10:12:31 AM
SEATTLE--(BUSINESS WIRE)--TapImmune Inc. (OTCQB: TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has filed a new patent application for a novel technology platform designed to enhance the visibility of cancer or infected cells to a patient’s immune system, a critical aspect of an effective vaccine.
Help employers find you! Check out all the jobs and post your resume.
comments powered by